Identification Name Hydroxychloroquine Accession Number DB01611 Type Small Molecule Groups Approved Description A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites.
Structure Synonyms (+-)-Hydroxychloroquine (±)-hydroxychloroquine 2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol 7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline 7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline 7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline 7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline Hidroxicloroquina Hydroxychloroquinum NSC4375 Oxichlorochine Oxichloroquine Polirreumin
External IDs Not Available Product Ingredients Approved Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Avera Mc Kennan Hospital 2015-03-24 Not applicable US Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Prasco, Laboratories 2014-12-12 Not applicable US Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2014-12-12 Not applicable US Mint-hydroxychloroquine Tablet 200 mg Oral Mint Pharmaceuticals Inc 2014-06-10 Not applicable Canada Mylan-hydroxychloroquine Tablet 200 mg Oral Mylan Pharmaceuticals 2004-05-21 Not applicable Canada Nu-hydroxyquine Tablet 200 mg Oral Nu Pharm Inc Not applicable Not applicable Canada Plaquenil Tablet, film coated 200 mg/1 Oral Sanofi Aventis 1955-04-18 Not applicable US Plaquenil Tablet 200 mg/1 Oral Carilion Materials Management 2013-06-28 Not applicable US Plaquenil Tablet 200 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2013-06-28 Not applicable US Plaquenil Tablet 200 mg Oral Sanofi Aventis 1957-12-31 Not applicable Canada Plaquenil Tablet 200 mg/1 Oral Concordia Pharmaceuticals, Inc 2013-06-28 Not applicable US Plaquenil Tablet 200 mg/1 Oral Covis Pharmaceuticals, Inc. 2013-06-28 2017-12-31 US Plaquenil Tablet 200 mg/1 Oral Av Kare, Inc. 2016-07-14 Not applicable US PMS-hydroxychloroquine Tablet 200 mg Oral Pharmascience Inc Not applicable Not applicable Canada Pro-hydroxyquine - 200 Tablet 200 mg Oral Pro Doc Limitee 2008-07-29 Not applicable Canada
Approved Generic Prescription Products Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-hydroxyquine Tablet 200 mg Oral Apotex Corporation 2002-12-13 Not applicable Canada Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2014-05-19 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral A S Medication Solutions 2016-03-24 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Cardinal Health 2008-08-05 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Cadila Pharnmaceuticals 2008-01-03 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Blenheim Pharmacal, Inc. 2013-12-20 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Ohm Laboratories, Inc. 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral A S Medication Solutions 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Enteral Mylan Pharmaceuticals 1998-06-18 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Cardinal Health 1995-11-30 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Dispensing Solutions, Inc. 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Rebel Distributors 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Physicians Total Care, Inc. 1996-07-09 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral A S Medication Solutions 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Zydus Pharmaceuticals Usa, Inc. 2008-01-03 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Golden State Medical Supply 2007-08-15 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Avera Mc Kennan Hospital 2015-08-31 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral West Ward Pharmaceutical 2007-08-15 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Aidarex Pharmaceuticals LLC 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Actavis Pharma Company 2016-03-24 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral A S Medication Solutions 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Ranbaxy Inc. 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Av Kare, Inc. 2012-02-29 2015-12-29 US Hydroxychloroquine Sulfate Tablet, coated 200 mg/1 Oral Watson Pharmaceuticals 1995-11-30 2016-03-05 US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Av Kare, Inc. 2014-05-19 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Enteral Mylan Institutional 2016-03-28 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Directrx 2014-01-01 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral bryant ranch prepack 2009-01-07 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral North Star Rx Llc 2015-12-18 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Sandoz 1995-11-30 Not applicable US Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2012-02-29 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 1995-11-30 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Amerincan Health Packaging 2008-08-05 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation 2008-01-03 Not applicable US Hydroxychloroquine Sulfate Tablet, film coated 200 mg/1 Oral Major 1995-11-30 Not applicable US Hydroxychloroquine Sulfate Tablet 200 mg/1 Oral Remedy Repack 2011-04-13 2016-10-13 US
Approved Over the Counter Products Not Available Unapproved/Other Products Not Available International Brands Name Company Axokine AstraZeneca Dolquine Inmunosyn HCQS Medigroup Polirreumin TRB Quensyl Sanofi
Brand mixtures Not Available Categories UNII 4QWG6N8QKH CAS number 118-42-3 Weight Average: 335.872 Chemical Formula C18 H26 ClN3 O InChI Key XXSMGPRMXLTPCZ-UHFFFAOYSA-N InChI InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
IUPAC Name 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
SMILES CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
Pharmacology Indication For the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax , P. malariae , P. ovale , and susceptible strains of P. falciparum . It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
Structured Indications Pharmacodynamics Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. The precise mechanism of action is not known.
Mechanism of action Although the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter DNA. Hydroxychloroquine has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown.
Target Kind Pharmacological action Actions Organism UniProt ID DNA Nucleotide yes cross-linking/alkylation
Human not applicable details Toll-like receptor 7 Protein yes antagonist
Human Q9NYK1 details Toll-like receptor 9 Protein yes antagonist
Human Q9NR96 details
Related Articles
Absorption Very rapidly and completely absorbed following oral administration.
Volume of distribution Not Available Protein binding Approximately 45%.
Metabolism
Partially hepatic, to active de-ethylated metabolites.
Route of elimination Not Available Half life Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.
Clearance Not Available Toxicity Symptoms of overdose include headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest. The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive bradycardia leading to ventricular fibrillation and/or arrest.
Affected organisms Pathways Not Available Pharmacogenomic Effects/ADRs Not Available Interactions Drug Interactions Drug Interaction Drug group Acebutolol The metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine. Approved Acepromazine The serum concentration of Acepromazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved Aceprometazine The serum concentration of Aceprometazine can be increased when it is combined with Hydroxychloroquine. Approved Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Hydroxychloroquine. Approved Albendazole The serum concentration of Albendazole can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Alimemazine The serum concentration of Alimemazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved Alprenolol The metabolism of Alprenolol can be decreased when combined with Hydroxychloroquine. Approved, Withdrawn Arotinolol The metabolism of Arotinolol can be decreased when combined with Hydroxychloroquine. Approved Artemether The risk or severity of adverse effects can be increased when Artemether is combined with Hydroxychloroquine. Approved Atenolol The metabolism of Atenolol can be decreased when combined with Hydroxychloroquine. Approved Befunolol The metabolism of Befunolol can be decreased when combined with Hydroxychloroquine. Experimental Benzimidazole The serum concentration of Benzimidazole can be decreased when it is combined with Hydroxychloroquine. Experimental Betaxolol The metabolism of Betaxolol can be decreased when combined with Hydroxychloroquine. Approved Bevantolol The metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine. Approved Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Hydroxychloroquine. Approved Bithionol The serum concentration of Bithionol can be decreased when it is combined with Hydroxychloroquine. Withdrawn BL-1020 The serum concentration of BL-1020 can be increased when it is combined with Hydroxychloroquine. Investigational Bopindolol The metabolism of Bopindolol can be decreased when combined with Hydroxychloroquine. Approved Bufuralol The metabolism of Bufuralol can be decreased when combined with Hydroxychloroquine. Experimental, Investigational Bupranolol The metabolism of Bupranolol can be decreased when combined with Hydroxychloroquine. Approved Carteolol The metabolism of Carteolol can be decreased when combined with Hydroxychloroquine. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Hydroxychloroquine. Approved, Investigational Celiprolol The metabolism of Celiprolol can be decreased when combined with Hydroxychloroquine. Approved, Investigational Chloroquine The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Chlorpromazine The serum concentration of Chlorpromazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved Dapsone The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone. Approved, Investigational Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Hydroxychloroquine. Approved Diethylcarbamazine The serum concentration of Diethylcarbamazine can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Hydroxychloroquine. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Hydroxychloroquine. Approved Esmolol The metabolism of Esmolol can be decreased when combined with Hydroxychloroquine. Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine. Approved Flubendazole The serum concentration of Flubendazole can be decreased when it is combined with Hydroxychloroquine. Approved, Withdrawn Fluphenazine The serum concentration of Fluphenazine can be increased when it is combined with Hydroxychloroquine. Approved Indenolol The metabolism of Indenolol can be decreased when combined with Hydroxychloroquine. Withdrawn Ivermectin The serum concentration of Ivermectin can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Labetalol The metabolism of Labetalol can be decreased when combined with Hydroxychloroquine. Approved Levamisole The serum concentration of Levamisole can be decreased when it is combined with Hydroxychloroquine. Vet Approved, Withdrawn Levobunolol The metabolism of Levobunolol can be decreased when combined with Hydroxychloroquine. Approved Lucanthone The serum concentration of Lucanthone can be decreased when it is combined with Hydroxychloroquine. Approved, Investigational Lumefantrine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Lumefantrine. Approved Mebendazole The serum concentration of Mebendazole can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Mefloquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine. Approved Mesoridazine The serum concentration of Mesoridazine can be increased when it is combined with Hydroxychloroquine. Approved Methotrimeprazine The serum concentration of Methotrimeprazine can be increased when it is combined with Hydroxychloroquine. Approved Methylene blue The serum concentration of Methylene blue can be increased when it is combined with Hydroxychloroquine. Investigational Metipranolol The metabolism of Metipranolol can be decreased when combined with Hydroxychloroquine. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Hydroxychloroquine. Approved, Investigational Moricizine The serum concentration of Moricizine can be increased when it is combined with Hydroxychloroquine. Approved, Withdrawn Nadolol The metabolism of Nadolol can be decreased when combined with Hydroxychloroquine. Approved Niclosamide The serum concentration of Niclosamide can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Oleandrin The serum concentration of Anvirzel can be increased when it is combined with Hydroxychloroquine. Experimental Ouabain The serum concentration of Ouabain can be increased when it is combined with Hydroxychloroquine. Approved Oxamniquine The serum concentration of Oxamniquine can be decreased when it is combined with Hydroxychloroquine. Approved Oxibendazole The serum concentration of Oxibendazole can be decreased when it is combined with Hydroxychloroquine. Investigational, Vet Approved Oxprenolol The metabolism of Oxprenolol can be decreased when combined with Hydroxychloroquine. Approved Penbutolol The metabolism of Penbutolol can be decreased when combined with Hydroxychloroquine. Approved, Investigational Perphenazine The serum concentration of Perphenazine can be increased when it is combined with Hydroxychloroquine. Approved Pindolol The metabolism of Pindolol can be decreased when combined with Hydroxychloroquine. Approved Piperazine The serum concentration of Piperazine can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Practolol The metabolism of Practolol can be decreased when combined with Hydroxychloroquine. Approved Praziquantel The serum concentration of Praziquantel can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Prochlorperazine The serum concentration of Prochlorperazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved Promazine The serum concentration of Promazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved Promethazine The serum concentration of Promethazine can be increased when it is combined with Hydroxychloroquine. Approved Propranolol The metabolism of Propranolol can be decreased when combined with Hydroxychloroquine. Approved, Investigational Pyrvinium The serum concentration of Pyrvinium can be decreased when it is combined with Hydroxychloroquine. Approved Quinacrine The serum concentration of Quinacrine can be decreased when it is combined with Hydroxychloroquine. Approved Sodium stibogluconate The serum concentration of Sodium stibogluconate can be decreased when it is combined with Hydroxychloroquine. Approved, Investigational Sotalol The metabolism of Sotalol can be decreased when combined with Hydroxychloroquine. Approved Suramin The serum concentration of Suramin can be decreased when it is combined with Hydroxychloroquine. Approved Thiabendazole The serum concentration of Thiabendazole can be decreased when it is combined with Hydroxychloroquine. Approved, Vet Approved Thiethylperazine The serum concentration of Thiethylperazine can be increased when it is combined with Hydroxychloroquine. Withdrawn Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Hydroxychloroquine. Withdrawn Timolol The metabolism of Timolol can be decreased when combined with Hydroxychloroquine. Approved Trifluoperazine The serum concentration of Trifluoperazine can be increased when it is combined with Hydroxychloroquine. Approved Triflupromazine The serum concentration of Triflupromazine can be increased when it is combined with Hydroxychloroquine. Approved, Vet Approved
Food Interactions Not Available References Synthesis Reference U.S. Patent 2,546,658.
General References Not Available External Links ATC Codes P01BA02 AHFS Codes Not Available PDB Entries Not Available FDA label Not Available MSDS Not Available Clinical Trials Clinical Trials Phase Status Purpose Conditions Count 0 Completed Supportive Care Liver Cirrhosis / Muscle Cramps 1 0 Completed Treatment Melanoma (Skin) 1 0 Completed Treatment Plasma Cell Myeloma 1 0 Terminated Treatment Malignant Neoplasm of Prostate 1 1 Active Not Recruiting Treatment Adult Solid Neoplasm 1 1 Active Not Recruiting Treatment Adult Solid Neoplasm / Hormone-Resistant Prostate Cancer / Recurrent Melanoma / Recurrent Prostate Carcinoma / Renal Cell Carcinoma Recurrent / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Skin Melanoma 1 1 Active Not Recruiting Treatment Melanoma 1 1 Active Not Recruiting Treatment Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma 1 1 Active Not Recruiting Treatment Unspecified Adult Solid Tumor, Protocol Specific 1 1 Completed Treatment Cystic Fibrosis (CF) 1 1 Completed Treatment Immunosuppression / Rheumatism 1 1 Completed Treatment Lymphangioleiomyomatosis 1 1 Completed Treatment Unspecified Adult Solid Tumor, Protocol Specific 1 1 Not Yet Recruiting Treatment Acute Myelogenous Leukaemia (AML) 1 1 Not Yet Recruiting Treatment Tumors, Solid 1 1 Recruiting Treatment Advanced Cancers 1 1 Recruiting Treatment Estrogen Receptor Positive Breast Cancer 1 1 Recruiting Treatment Malignant Solid Tumours 1 1 Recruiting Treatment Tumors, Solid 1 1 Terminated Treatment Bone Metastases / Unspecified Adult Solid Tumor, Protocol Specific 1 1 Terminated Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 1 Terminated Treatment Renal Cell Adenocarcinoma 1 1 Unknown Status Treatment Human Immunodeficiency Virus (HIV) Infections 1 1, 2 Active Not Recruiting Treatment Adenocarcinomas / Malignant Neoplasm of Colon / Metastasis / Rectal Carcinoma 1 1, 2 Active Not Recruiting Treatment Histological Evidence of Metastatic Clear Cell Renal Cell Carcinoma / Metastatic Clear Cell Renal Cell Carcinoma / Of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous / That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens / Therapy With Bevacizumab, IL2, or Interferon Are Permitted / With Evidence of Progressive Disease on or Within 6 Months 1 1, 2 Completed Diagnostic Systemic Lupus Erythematosus (SLE) 1 1, 2 Completed Treatment Acute HIV Infection 1 1, 2 Not Yet Recruiting Treatment Diabetes Type Two 1 1, 2 Not Yet Recruiting Treatment Platinum-resistant Epithelial Ovarian Cancer 1 1, 2 Recruiting Treatment Advanced Adenocarcinoma / Metastatic Adenocarcinoma 1 1, 2 Recruiting Treatment Advanced BRAF Mutant Melanoma 1 1, 2 Recruiting Treatment Disseminated Sclerosis 1 1, 2 Recruiting Treatment Metastatic Renal Cell Carcinoma 1 1, 2 Terminated Treatment Cancer, Breast 1 1, 2 Terminated Treatment Chronic Hepatitis C Infection 1 1, 2 Terminated Treatment Lung Cancers 1 1, 2 Unknown Status Treatment Brain and Central Nervous System Tumors 1 1, 2 Unknown Status Treatment Malignant Neoplasm of Pancreas 1 1, 2 Unknown Status Treatment Multiple Myeloma and Plasma Cell Neoplasm 1 1, 2 Unknown Status Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Active Not Recruiting Treatment Glioblastomas 1 2 Active Not Recruiting Treatment Malignant Neoplasm of Pancreas 2 2 Active Not Recruiting Treatment Malignant Neoplasm of Prostate 1 2 Active Not Recruiting Treatment Non-Small-Cell Lung Carcinoma (NSCLC) 1 2 Completed Treatment Advanced Non-Small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer 1 2 Completed Treatment Colorectal Cancers 1 2 Completed Treatment Lichen Planus, Oral 1 2 Completed Treatment Malignant Neoplasm of Prostate 1 2 Completed Treatment Osteoarthritis of the Knees 1 2 Not Yet Recruiting Prevention Systemic Lupus Erythematosus Encephalitis 1 2 Not Yet Recruiting Treatment Hepatocellular Cancer 1 2 Not Yet Recruiting Treatment Lung Cancer Small Cell Lung Cancer (SCLC) 1 2 Recruiting Prevention Autoantibody-Associated Heart Block / Congenital Heart Block / Neonatal Lupus 1 2 Recruiting Prevention Healthy Participants / Healthy Volunteers / Rheumatoid Arthritis (RA) Prevention / Rheumatoid Arthritis Prevention 1 2 Recruiting Treatment Antiphospholipid Syndrome (APS) 1 2 Recruiting Treatment Breast Cancer Stage IIB 1 2 Recruiting Treatment Children´s Interstitial Lung Disease / Diffuse Parenchymal Lung Diseases / Interstitial Lung Disease (ILD) 1 2 Recruiting Treatment Colorectal Cancers 1 2 Recruiting Treatment Diabetes Mellitus Type 2 With Hyperglycemia 1 2 Recruiting Treatment Hydroxychloroquine / IgA Patients 1 2 Recruiting Treatment Malignant Neoplasm of Pancreas 1 2 Recruiting Treatment Multiple Sclerosis, Primary Progressive 1 2 Recruiting Treatment Porphyria Cutanea Tarda 1 2 Terminated Treatment Arteriosclerosis / Cardiovascular Disease (CVD) / Kidney Failure,Chronic 1 2 Terminated Treatment B-Cell Chronic Lymphocytic Leukemia 1 2 Terminated Treatment Malignant Neoplasm of Prostate 1 2 Terminated Treatment Sarcomas 1 2 Unknown Status Prevention Flu caused by Influenza 1 2 Unknown Status Treatment Cancer, Breast 1 2 Unknown Status Treatment Crohn's Disease (CD) 1 2 Unknown Status Treatment Human Immunodeficiency Virus (HIV) Infections 1 2 Unknown Status Treatment Leukemias 1 2 Withdrawn Treatment Abortions spontaneous / Recurrent Pregnancy Losses 1 3 Completed Supportive Care Graft Versus Host Disease (GVHD) 1 3 Completed Treatment Autoimmune Diseases / Eye Dryness / Sjogren's Syndrome 1 3 Completed Treatment Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus 1 3 Completed Treatment Giant Cells Arteritis 1 3 Completed Treatment Insulin Resistance / Rheumatoid Arthritis 1 3 Completed Treatment Primary Sjögren's Syndrome 1 3 Completed Treatment Rheumatoid Arthritis 4 3 Completed Treatment Sarcoidosis, Pulmonary 1 3 Completed Treatment Seronegative Spondyloarthropathies 1 3 Completed Treatment Synovitis of osteoarthritis 1 3 Not Yet Recruiting Treatment First Trimester Abortion / Recurrent Miscarriages 1 3 Recruiting Treatment Thrombocytopenias 1 3 Terminated Prevention Antiphospholipid Syndrome 1 4 Completed Basic Science Pre-Diabetic 1 4 Completed Treatment Alopecia Areata (AA) 1 4 Completed Treatment Borrelia Infection / Lyme Disease 1 4 Completed Treatment Primary IgA Nephropathy 1 4 Completed Treatment Rheumatoid Arthritis 3 4 Not Yet Recruiting Treatment Coronary Artery Disease 1 4 Not Yet Recruiting Treatment Cutaneous Lupus / Juvenile SLE / Systemic Lupus Erythematosus (SLE) 1 4 Not Yet Recruiting Treatment Individuals Undergoing Cardiac and General Surgery 1 4 Not Yet Recruiting Treatment Insufficient Response to Methotrexate / Rheumatoid Arthritis 1 4 Recruiting Treatment Acute Coronary Syndromes (ACS) / Antirheumatic Agents / Cardiovascular Disease (CVD) / Hydroxychloroquine / Inflammatory Reaction / Myocardial Infarction (MI) / Unstable Angina (UA) 1 4 Recruiting Treatment Primary IgA Nephropathy 1 4 Recruiting Treatment Rheumatoid Arthritis 3 Not Available Active Not Recruiting Basic Science HIV Disease 1 Not Available Completed Not Available Sjögren's Syndrome / Xerostomia 1 Not Available Completed Treatment Hashimoto's Thyroiditis 1 Not Available Completed Treatment Rheumatoid Arthritis 1 Not Available Not Yet Recruiting Not Available Autoimmune Diseases 1 Not Available Recruiting Not Available Type 2 Diabetes Mellitus 1 Not Available Recruiting Basic Science Insulin Resistance 1 Not Available Recruiting Treatment Rheumatoid Arthritis 1 Not Available Recruiting Treatment Systemic Lupus Erythematosus (SLE) 1 Not Available Unknown Status Treatment Hashimoto's Thyroiditis 1 Not Available Withdrawn Treatment Chronic Urticaria 1
Pharmacoeconomics Manufacturers Not Available Packagers Dosage forms Form Route Strength Tablet Oral 200 mg/1 Tablet, coated Oral 200 mg/1 Tablet, film coated Enteral 200 mg/1 Tablet Oral 200 mg Tablet, film coated Oral 200 mg/1
Prices Unit description Cost Unit Hydroxychloroquine sulf powder 4.8USD g Plaquenil 200 mg tablet 3.14USD tablet Hydroxychloroquine Sulfate 200 mg tablet 1.28USD tablet Hydroxychloroquine 200 mg tablet 1.17USD tablet Plaquenil Sulfate 200 mg Tablet 0.66USD tablet Apo-Hydroxyquine 200 mg Tablet 0.35USD tablet Mylan-Hydroxychloroquine 200 mg Tablet 0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available Properties State Solid Experimental Properties Property Value Source melting point (°C) 89-91 U.S. Patent 2,546,658.
Predicted Properties Predicted ADMET features Property Value Probability Human Intestinal Absorption + 0.9892 Blood Brain Barrier + 0.5602 Caco-2 permeable - 0.5154 P-glycoprotein substrate Substrate 0.8348 P-glycoprotein inhibitor I Non-inhibitor 0.7297 P-glycoprotein inhibitor II Inhibitor 0.5106 Renal organic cation transporter Non-inhibitor 0.5742 CYP450 2C9 substrate Non-substrate 0.8239 CYP450 2D6 substrate Non-substrate 0.9117 CYP450 3A4 substrate Non-substrate 0.5384 CYP450 1A2 substrate Non-inhibitor 0.5864 CYP450 2C9 inhibitor Non-inhibitor 0.8457 CYP450 2D6 inhibitor Non-inhibitor 0.6111 CYP450 2C19 inhibitor Non-inhibitor 0.8782 CYP450 3A4 inhibitor Non-inhibitor 0.6287 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7058 Ames test AMES toxic 0.6907 Carcinogenicity Non-carcinogens 0.837 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6348 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6798 hERG inhibition (predictor II) Inhibitor 0.7173
ADMET data is predicted using
admetSAR , a free tool for evaluating chemical ADMET properties. (
23092397 )
Spectra Mass Spec (NIST) Not Available Spectra Taxonomy Description This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system. Kingdom Organic compounds Super Class Organoheterocyclic compounds Class Quinolines and derivatives Sub Class Aminoquinolines and derivatives Direct Parent 4-aminoquinolines Alternative Parents Chloroquinolines / Secondary alkylarylamines / Aminopyridines and derivatives / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives show 3 moreSubstituents Chloroquinoline / 4-aminoquinoline / Haloquinoline / Aminopyridine / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Pyridine / Benzenoid / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / 1,2-aminoalcohol / Secondary amine / Azacycle / Alkanolamine / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Organochloride / Organohalogen compound / Alcohol / Primary alcohol / Organic nitrogen compound / Organopnictogen compound / Organic oxygen compound / Amine / Aromatic heteropolycyclic compound show 18 moreMolecular Framework Aromatic heteropolycyclic compounds External Descriptors tertiary amino compound, organochlorine compound, secondary amino compound, primary alcohol, aminoquinoline (CHEBI:5801 ) 
